Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07689006 · ClinicalTrials.gov registry record
Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 341
- Enrollment target
NCT07689006 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 341 participants.
The verdict
NCT07689006 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 341 participants
- Enrollment target
Study Summary
This retrospective observational study will use data from the OneOncology United States database to evaluate clinical outcomes in adults with relapsed/refractory multiple myeloma who received pomalidomide-containing or non-pomalidomide-containing treatment as second-line or third-line therapy after prior exposure to lenalidomide and a proteasome inhibitor.
Interventions
- DRUG Pomalidomide-containing regimens
- DRUG Non-pomalidomide-containing regimens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 341 participants |
| Start Date | 2024-12-23 |
| Est. Completion | 2025-03-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07689006
The ClinicalTrials.gov registry entry for NCT07689006 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 341 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pomalidomide-containing regimens is the first listed.
NCT07689006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07689006 about?
NCT07689006 is a clinical study titled "Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens". This retrospective observational study will use data from the OneOncology United States database to evaluate clinical outcomes in adults with relapsed/refractory multiple myeloma who received pomalidomide-containing or non-pomalidomide-containing treatment as second-line or third-line therapy after ...
What is the current status of trial NCT07689006?
This trial is currently completed. The enrollment target is 341 participants. The study started on 2024-12-23. Estimated completion is 2025-03-28.
What interventions are being tested in trial NCT07689006?
The interventions under investigation include: Pomalidomide-containing regimens (DRUG), Non-pomalidomide-containing regimens (DRUG).
Who is sponsoring clinical trial NCT07689006?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.